Abstract | OBJECTIVE: METHODS: The Surgery for Trichiasis, Antibiotics to Prevent Recurrence (STAR) trial is a randomized, single-masked, clinical trial conducted in southern Ethiopia, a region where trachoma is hyperendemic. A total of 1452 patients who underwent trichiasis surgery were randomly assigned at a 2:1 ratio to either a single dose of oral azithromycin (1 g) or topical tetracycline (twice per day for 6 weeks) following surgery. MAIN OUTCOME MEASURES: Recurrence of trichiasis within 3 years following surgery. RESULTS: CONCLUSION:
Trichiasis recurrence rates in the STAR trial remained low for up to 3 years following surgery. The protective effect of a single dose of azithromycin was less than at 1 year and, although not statistically significant, was still suggestive up to 3 years following trichiasis surgery. APPLICATION TO CLINICAL PRACTICE: A single dose of azithromycin after surgery remains an integral component of the World Health Organization's strategy for the elimination of trachoma by the year 2020.
|
Authors | Fasika Woreta, Beatriz Munoz, Emily Gower, Wondu Alemayehu, Sheila K West |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 130
Issue 4
Pg. 427-31
(Apr 2012)
ISSN: 1538-3601 [Electronic] United States |
PMID | 22159169
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Anti-Bacterial Agents
- Azithromycin
- Tetracycline
|
Topics |
- Administration, Oral
- Administration, Topical
- Anti-Bacterial Agents
(administration & dosage)
- Azithromycin
(administration & dosage)
- Endemic Diseases
- Ethiopia
(epidemiology)
- Female
- Follow-Up Studies
- Humans
- Incidence
- Male
- Middle Aged
- Ophthalmologic Surgical Procedures
- Secondary Prevention
- Single-Blind Method
- Tetracycline
(administration & dosage)
- Treatment Outcome
- Trichiasis
(drug therapy, epidemiology, prevention & control, surgery)
|